Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 4
2006 6
2007 1
2009 1
2010 2
2011 2
2020 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, Im SA, Kim SB, Johnston SR, Chan A, Goel S, Catron K, Chapman SC, Price GL, Yang Z, Gainford MC, André F. Tolaney SM, et al. Among authors: gainford mc. Lancet Oncol. 2020 Jun;21(6):763-775. doi: 10.1016/S1470-2045(20)30112-1. Epub 2020 Apr 27. Lancet Oncol. 2020. PMID: 32353342 Clinical Trial.
An open label, randomized phase 2 trial assessing the impact of food on the tolerability of abemaciclib in patients with advanced breast cancer.
Lim E, Boyle F, Okera M, Loi S, Goksu SS, van Hal G, Chapman SC, Gable JC, Chen Y, Price GL, Hossain AM, Gainford MC, Ezquerra MB. Lim E, et al. Among authors: gainford mc. Breast Cancer Res Treat. 2022 Oct;195(3):275-287. doi: 10.1007/s10549-022-06690-5. Epub 2022 Aug 1. Breast Cancer Res Treat. 2022. PMID: 35915198 Free PMC article. Clinical Trial.
Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
Goldstein D, Gainford MC, Brown C, Tebbutt N, Ackland SP, van Hazel G, Jefford M, Abdi E, Selva-Nayagam S, Gebski V, Miller D, Shannon J. Goldstein D, et al. Among authors: gainford mc. Cancer Chemother Pharmacol. 2011 Mar;67(3):519-25. doi: 10.1007/s00280-010-1351-8. Epub 2010 May 12. Cancer Chemother Pharmacol. 2011. PMID: 20461378 Clinical Trial.
Health-Related Quality of Life in MONARCH 3: Abemaciclib plus an Aromatase Inhibitor as Initial Therapy in HR+, HER2- Advanced Breast Cancer.
Goetz MP, Martin M, Tokunaga E, Park IH, Huober J, Toi M, Stoffregen C, Shekarriz S, Andre V, Gainford MC, Price GL, Johnston S. Goetz MP, et al. Among authors: gainford mc. Oncologist. 2020 Sep;25(9):e1346-e1354. doi: 10.1634/theoncologist.2020-0084. Epub 2020 Jun 24. Oncologist. 2020. PMID: 32536013 Free PMC article. Clinical Trial.
Breast cancer in pregnancy: are taxanes safe?
Gainford MC, Clemons M. Gainford MC, et al. Clin Oncol (R Coll Radiol). 2006 Mar;18(2):159. doi: 10.1016/j.clon.2005.12.002. Clin Oncol (R Coll Radiol). 2006. PMID: 16523825 No abstract available.
Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.
Stockler MR, Harvey VJ, Francis PA, Byrne MJ, Ackland SP, Fitzharris B, Van Hazel G, Wilcken NR, Grimison PS, Nowak AK, Gainford MC, Fong A, Paksec L, Sourjina T, Zannino D, Gebski V, Simes RJ, Forbes JF, Coates AS. Stockler MR, et al. Among authors: gainford mc. J Clin Oncol. 2011 Dec 1;29(34):4498-504. doi: 10.1200/JCO.2010.33.9101. Epub 2011 Oct 24. J Clin Oncol. 2011. PMID: 22025143 Clinical Trial.
17 results